A first-mover, AI-enabled point-of-care EEG platform with razor-and-blade economics—but the upside is highly dependent on patent protection and reimbursement catalysts.
Overview
CeriBell (CBLL) is a commercial-stage medtech company aiming to make continuous EEG a routine “vital sign” in U.S. acute care by replacing slow, technician-dependent legacy EEG with a portable, rapid-deploy point-of-care system. Its Ceribell System pairs disposable, easy-to-apply headbands/headcaps and compact bedside recorders with the Clarity cloud-based, AI/ML diagnostic subscription that provides continuous, real-time seizure (and now delirium) burden insights without requiring immediate neurologist availability. The company monetizes via a high-margin razor-and-blade model: in 2025 product revenue was $67.3M (+34% YoY) and subscription revenue was $21.7M (+41% YoY), for total revenue of $89.1M (+36% YoY) and ~88% gross margin. Adoption is accelerating across acute care hospitals (ICUs/EDs), reaching 647 active accounts by end-2025 (+118 net new). The thesis is supported by strong clinical and economic evidence (improved sensitivity, faster time-to-EEG, reduced ICU length-of-stay), and by a structurally expanding TAM: from a ~$2.5B seizure market to ~$3.5B following FDA clearances for pediatrics/neonates and a new ~$1B delirium monitoring market. With first-mover advantages in AI point-of-care neuro-monitoring, the company sits at the center of a shift in neurologic triage—but near-term outcomes are meaningfully influenced by patent litigation and reimbursement catalysts.